As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard ...

Pfizer Inc.’s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

While it is still a long way behind its rivals, Pfizer said it has decided that the once-daily version of danuglipron could still be a player in the market, which has a long list of candidates in ...

Story of activist fund Starboard Value taking $1B position in Pfizer is grabbing headlines the last few days. Read why I ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker struggles with its post-pandemic financial ...

Three Motley Fool contributors believe they have identified magnificent dividend stocks to buy in October -- and all of them are drugmakers. Here's why they picked AbbVie ( ABBV -0.59%), Amgen ( AMGN ...

Pfizer will also earn plenty of other brand-new products. It recently advanced once-daily danuglipron in weight loss to pivotal clinical trials. The company dropped the twice-daily version of this ...

The lucrative GLP-1 weight loss field is growing rapidly. Pfizer's candidate, oral danuglipron, recently performed well in a phase 2 study. Then, there are the company's efforts in oncology.